#United States #Henderson #VolitionRx #sepsis #NETosis

VolitionRx Unveils High Throughput Model for NETosis Research

In a landmark achievement, VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering epigenetics firm, has introduced its first commercial application of an advanced High Throughput Synthetic Sepsis model. This innovative method allows for the real-time measurement of Neutrophil Extracellular Traps (NETs) activation within whole blood, aiming to facilitate the development of new therapeutic options against sepsis and related conditions.

Dr. Jasmine Kway, Volition’s CEO of Singapore operations and the Commercial Lead for Nu.Q® Discover, highlighted the breakthrough, stating, "Our High Throughput NETs model is a crucial advancement in understanding the biology of neutrophils. Historically, understanding NETs-related diseases in vivo has presented significant challenges."

Traditionally, research into NETosis has largely relied on isolated neutrophil studies, which can overlook essential interactions occurring within whole blood. By enabling more accurate measurements of NET formation, VolitionRx’s model opens new therapeutic avenues for NETosis-related diseases.

Key Features of the High-Throughput Model

• - Real-time Monitoring: The new methodology quantitatively assesses the release of NETs in real time.
• - No Isolation Required: The model eliminates cell isolation steps that often yield unreliable cellular responses.
• - Foundational Research Support: This innovation builds upon previous research documented in the Journal of Thrombosis and Hemostasis.
• - Physiologically Relevant Environment: The model provides a more accurate simulation of the human body's conditions for studying neutrophil activity.

According to Dr. Terry Kelly, Chief Innovation Officer at Volition America, this achievement marks the culmination of extensive research and development over the last two years. He confirmed, "We can now induce and inhibit NET formation in healthy blood samples using automated high-throughput systems. The growing body of scientific literature on NETs reflects an urgent need for biopharmaceutical companies to understand NET biology better and develop new treatment strategies."

This novel technology addresses a vital gap in traditional neutrophil research. By facilitating direct measurement of NETs in whole blood, it mitigates the risk of distorted cellular responses that arise from isolation procedures, a point emphasized in recent discussions within the scientific community.

The Impact of Sepsis and NETs

Sepsis is a severe condition caused by an overactive immune response to infection, responsible for around 370,000 deaths in the U.S. annually. Neutrophils play a crucial role in the immune response, clearing pathogens through the release of NETs during NETosis.

While NETs are essential for trapping pathogens, excessive production can lead to tissue damage and worsening disease outcomes during inflammation. Historically, studies on NETosis have relied on artificial stimulation in isolated systems, obscuring the natural processes. A better understanding of natural NET activation is essential to development of reliable biomarkers and insights into the regulation of neutrophil-associated diseases in living organisms.

VolitionRx is committed to creating accessible, cost-effective blood tests designed to aid in the diagnosis and monitoring of various life-changing diseases for both humans and animals.

About Volition

VolitionRx is a diversified company striving to enhance epigenetic science to improve detection and treatment outcomes for severe diseases. They focus on early diagnosis and monitoring to not only extend survival for affected individuals but also to enhance their quality of life. The company’s research capabilities are based in Belgium, complemented by an innovation lab and offices in the U.S., London, and Singapore.

For more details, visit Volition's website at www.volition.com.